Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular events originating in pulmonary ECs (P-ECs) may contribute to the PA-SMC hyperplasia in PH. Thus, we exposed cultured human PA-SMC to medium conditioned by P-EC from patients with idiopathic PH (IPH) or controls and found that IPH P-EC-conditioned medium increased PA-SMC proliferation more than control P-EC medium. Levels of FGF2 were increased in the medium of IPH P-ECs over controls, while there was no detectable difference in TGF-beta1, PDGF-BB, or EGF levels. No difference in FGF2-induced proliferation or FGF receptor type 1 (FGFR1) mRNA levels was detected between IPH and control PA-SMCs. Knockdown of FGF2 in P-EC using siRNA reduced the PA-SMC growth-stimulating effects of IPH P-EC medium by 60% and control P-EC medium by 10%. In situ hybridization showed FGF2 overproduction predominantly in the remodeled vascular endothelium of lungs from patients with IPH. Repeated intravenous FGF2-siRNA administration abolished lung FGF2 production, both preventing and nearly reversing a rat model of PH. Similarly, pharmacological FGFR1 inhibition with SU5402 reversed established PH in the same model. Thus, endothelial FGF2 is overproduced in IPH and contributes to SMC hyperplasia in IPH, identifying FGF2 as a promising target for new treatments against PH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelial/Pericyte Interactions
Armulik, A., Abramsson, A., & Betsholtz, C. (2005) · Circulation Research · doi:10.1161/01.res.0000182903.16652.d7 · Cited by 2,048
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Cited by
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
Rabinovitch, M., Guignabert, C., Humbert, M., & Nicolls, M. R. (2014) · Circulation Research · doi:10.1161/circresaha.113.301141 · Cited by 1,029
Self-citationMechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Hassoun, P. M., Mouthon, L., Barberà, J. A., Eddahibi, S., Flores, S. C., Grimminger, F., Jones, P. L., Maitland, M. L., Michelakis, E. D., Morrell, N. W., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.006 · Cited by 710
Self-citationPulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Self-citationRelevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Tuder, R. M., Archer, S. L., Dorfmüller, P., Erzurum, S. C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K. R., & Morrell, N. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.025 · Cited by 585
Self-citationKim, J., Kang, Y., Kojima, Y., Lighthouse, J. K., Hu, X., Aldred, M. A., McLean, D. L., Park, H., Comhair, S. A., Greif, D. M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3040 · Cited by 356
Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension
de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., François, C., Schalij, I., Dorfmüller, P., Simonneau, G., Fadel, E., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0411oc · Cited by 346
Self-citationCell Death in the Lung: The Apoptosis–Necroptosis Axis
Sauler, M., Bazan, I. S., & Lee, P. J. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114320 · Cited by 326
Endothelial cells in the pathogenesis of pulmonary arterial hypertension
Evans, C. E., Cober, N. D., Dai, Z., Stewart, D. J., & Zhao, Y.-Y. (2021) · European Respiratory Journal · doi:10.1183/13993003.03957-2020 · Cited by 325
Targeted therapies in pulmonary arterial hypertension
Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., Algalarrondo, V., Price, L. C., Savale, L., Sitbon, O., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.002 · Cited by 213
“specific inhibitors (TKIs) have been shown to exert beneficial effects in rodent models (Merklinger et al., 2005; Schermuly et al., 2005; Perros et al., 2008; Izikki et al., 2009; Tu et al., 2011, 2012).”
BackgroundSelf-citationRicard, N., Tu, L., Le Hiress, M., Huertas, A., Phan, C., Thuillet, R., Sattler, C., Fadel, E., Seferian, A., Montani, D., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007469 · Cited by 208
“This overexpression of endothelial-derived FGF-2 contributes significantly not only to SM hyperplasia by a paracrine action but also to the abnormal endothelial phenotype by an autocrine action.(13,16,22) Here, we showed that overabundance of FGF-2 in iPAH EC conditioned media contributed also to exaggerated migration…”
BackgroundMethodSelf-citationThe cancer theory of pulmonary arterial hypertension
Boucherat, O., Vitry, G., Trinh, I., Paulin, R., Provencher, S., & Bonnet, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217701438 · Cited by 202
“Like fibroblast growth factor-2 (FGF2), insulin-like growth factor 1 (IGF-1), and endothelin-1, PDGF also actively participates in mitogenic signaling and thickening of the pulmonary vascular media.(11,12) The binding of these signaling molecules to their receptors activates various interconnected signaling pathways s…”
BackgroundPullamsetti, S. S., Savai, R., Seeger, W., & Goncharova, E. A. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201606-1226pp · Cited by 158
FGF signaling is required for anterior but not posterior specification of the murine liver bud
Wang, J., Rhee, S., Palaria, A., & Tremblay, K. D. (2015) · Developmental Dynamics · doi:10.1002/dvdy.24215 · Cited by 40
“…requirements of FGF signaling during liver budding in the context of the whole embryo using the FGFR-specific tyrosine kinase small molecule inhibitor, SU5402 (Mohammadi et al., 1997; Poss et al., 2000; Hoffman et al., 2002; Dell’Era et al., 2003; Izikki et al., 2009; Wandzioch and Zaret, 2009).”
BackgroundMethod
Metadata
- Authors
- Izikki, M., Guignabert, C., Fadel, E., Humbert, M., Tu, L., Zadigue, P., Dartevelle, P., Simonneau, G., Adnot, S., Maitre, B., Raffestin, B., & Eddahibi, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-03-02
- Volume
- 119
- Issue
- 3
- Pages
- 512-523
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2058923462
- Cited by
- 217
- References
- 2
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.